ページ 1 から 26 結果
Obesity is a life-threatening disorder in which there is an increased risk of morbidity and mortality arising from concomitant diseases such as type II diabetes, hypertension, stroke, cancer, and gallbladder disease.
Obesity is now a major healthcare issue in the Western World and increasingly in
Obesity is a life-threatening disorder in which there is an increased risk of morbidity and mortality arising from concomitant diseases such as type II diabetes, hypertension, stroke, cancer, and gallbladder disease.
Obesity is now a major healthcare issue in the Western World and increasingly in
Obesity is a life-threatening disorder in which there is an increased risk of morbidity and mortality arising from concomitant diseases such as type II diabetes, hypertension, stroke, cancer, and gallbladder disease.
Obesity is now a major healthcare issue in the Western World and increasingly in
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated cation channels in the central nervous system (CNS) and the peripheral nervous system (PNS). The nAChRs serve a wide range of physiological functions, and have been implicated in a number of pathological
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated cation channels in the central nervous system (CNS) and the peripheral nervous system (PNS). The nAChRs serve a wide range of physiological functions, and have been implicated in a number of pathological
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the
FIELD OF THE INVENTION
The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty
FIELD OF THE INVENTION
The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty
BACKGROUND OF THE INVENTION
The endogenous cholinergic neurotransmitter, acetylcholine, exert its biological effect via two types of cholinergic receptors; the muscarinic ACh receptors and the nicotinic ACh receptors. As it is well established that muscarinic ACh receptors dominate quantitatively
The invention relates to 6H-oxazolo[4,5-e]indole derivatives of the formula I
##STR00002## in which R.sup.1 is H or Het.sup.1, R.sup.2 is H, A, cycloalkyl, --(CH.sub.2).sub.p--N(R.sup.5).sub.2, --(CH.sub.2).sub.p--OR.sup.5, --(CH.sub.2).sub.n--Ar or --(CH.sub.2).sub.n-Het, R.sup.3 is H, Hal, OH, OA
The invention relates to 6H-oxazolo[4,5-e]indole derivatives of the formula I
##STR00002## in which
R.sup.1 is H or Het.sup.1,
R.sup.2 is H, A, cycloalkyl, --(CH.sub.2).sub.p--N(R.sup.5).sub.2, --(CH.sub.2).sub.p--OR.sup.5, --(CH.sub.2).sub.n--Ar or --(CH.sub.2).sub.n-Het,
R.sup.3 is H, Hal, OH, OA
The invention relates to dihydroimidazo[4,5-e]indole and 7H-pyrrolo-[3,2-]quinoxaline derivatives of the formula I
##STR00002## in which A-B-D is --NR.sup.6--CR.sup.2.dbd.N--, --N.dbd.CR.sup.2--NR.sup.6-- or --N.dbd.CR.sup.7--CR.sup.8.dbd.N--, R.sup.1 is H or Het.sup.1, R.sup.2 is H, A, cycloalkyl,